Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Sunday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Stock Performance

ADXS opened at $0.03 on Friday. The company has a fifty day moving average price of $0.03 and a two-hundred day moving average price of $0.06. The firm has a market capitalization of $1.15 million, a PE ratio of 0.00 and a beta of 1.62. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.